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ABSTRACT 
 
Aims: Endothelin-1 (ET-1) is a potent vasoconstrictive peptide, and its activity is mediated by the 
type A receptor (EDNRA). This action may play a significant role in the etiology of hypertension. 
There are different works that shows an association between certain polymorphisms of endothelin 
axis and clinical phenotype of hypertension. We describe the genetic variability +138/ex1 
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insertion/deletion (I/D) adenosine (A) in the ET-1 gene and polymorphism thymidine/cytosine (T/C) 
His323His in the EDNRA gene associated at the clinical variability in hypertensive patients. 
Study Design: Observational, transversal and analytical study. 
Place and Duration of Study: Hypertension Service at the Internal Medicine Department of 
Córdoba Hospital, and Biochemical and Molecular Biology Department in School of Medicine, 
National University of Cordoba, Argentine. Patients considered hypertensive between April 2009 
and April 2010. 
Methodology: Were assessed 136 patients serum lipid profiles, renal and hepatic functions and 
were taken Thoracic X-rays, electrocardiograms, and echocardiographs. DNA extracted from 
circulating leukocyte were used to analyze the polymorphisms of genes by PCR-RFLP. 
Results: For the polymorphisms of Receptor A from Endothelin -1 studied the presence of 
cytosine homozygous genotype was less frequent in males (P = .02). For both genders, the same 
genotype was associated to low plasma alkaline phosphatase activity and cholesterol levels. The 
presence of thymidine nucleotide allele correlated with plasma alkaline phosphatase activity and 
cholesterol levels. The Thymidine allele correlated with the degree of cardiovascular compromise   
(r = 0.54, P= .002). For the genetic variant in the ET-1 gene, the homozygous adenine deletion 
was associated to normal plasma levels of glutamate/pyruvate transaminase enzyme activity, uric 
acid concentration, cholesterol, and Low Density Lipoprotein in hypertensive subjects without 
clinical risk. 
Conclusion: We observed a gender-specific protective effect for EDNRA gene variations, the 
subjects that carried the TT genotype presented more aggressive symptomatology. These results 
show an association between plasmatic biochemical parameters, the clinical condition, and 
polymorphisms in the endothelin axis genes. 
 
 
Keywords: Endothelin-1 gene; endothelin receptor a gene; genetic variation; hypertension.  
 
ABBREVIATIONS 
 
Endothelin-1: ET-1; type A receptor from Endotelin 1: EDNRA; Polymorphisms +138/exon1 
insertion/deletion of adenosine in the ET-1    gene: +138/ex1 I/D A ET-1 gene polymorphism; 
thymidine/cytosine in the EDNRA gene: (T/C) His323His EDNRA gene; Polymerase chain reaction and 
restriction fragment analysis: PCR-RFLP; Genotype CC from polymorphisms T/C His323His EDNRA 
gene: CC genotype; AlleleThymidine from T/C His323His EDNRA gene: T allele; Genotype 
deletion/deletion from +138/ex1 I/D A ET-1 gene: D/D genotype; LDL: Low-density lipoprotein; 
Hypertension: HT; Untranslated region: UTR; Messenger Ribonucleotide acid: mRNA; Insertion allele 
from +138/ex1 I/D A ET-1 gene: I allele;  The Seventh Report of the Joint National Committee: JNC 
VII; electrocardiogram: ECG; 2-dimensional color Doppler transthoracic echocardiograph:    EcoCG; 
thoracic X-rays: Thoracic Rx; single nucleotide polymorphisms: SNPs; glutamic/pyruvate 
transaminase: GPT; uric acid: UA; alkaline phosphatase:  AP. 
 
1. INTRODUCTION  
 
Hypertension (HT) has a multifactorial 
pathogenesis that involves genetic and 
environmental factors that lead to increased 
arterial pressure. It is widely accepted that 
hereditary predisposition can induce the 
endothelial cell dysfunction and damage, thus 
contribute to HT development and its more 
frequent clinical manifestations [1]. 
 
Experimental and clinical evidence has shown 
that endothelin-1 (ET-1) plays an important role 
in vascular system pathophysiology due to its 
vasoconstrictory and hypertrophic actions. The 
interactions between ET-1 and its type A 
receptor (EDNRA) in vascular smooth muscle 
cells are the primary cause of ET-1-related 
vasoconstriction [2]. 
 
Several studies have shown that genetic variants 
in the endothelin system could influence HT and 
its clinical phenotypes [3-6]. One ET-1 gene 
polymorphism that has been studied is the 
insertion (I) or deletion (D) of an adenine (A) 
nucleotide at position 138 in exon 1, which 
corresponds to the 5’ untranslated region (UTR) 
of the mRNA. This genetic variant has been 
shown to be associated to alterations in blood 
pressure values [7]. Spinarova et al. [8] have    
found a low relative risk of HT development in 
individuals with cardiac insufficiency and 
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increased levels of plasma endothelin in 
heterozygote subjects with the I/D variant. 
Popowski et al. [9] reported that in human 
umbilical vein endothelial cells derived from 
homozygotes for the I allele, had significantly 
increased ET-1 protein expression levels, due to 
mRNA stability. Similarly, significantly higher 
plasma ET-1 concentrations were observed by 
Tanaka et al. [10] in Japanese patients with the I 
allele. Furthermore, the thymidine-to-cytosine 
(T/C) nucleotide change at position 69 in exon 6 
of the EDNRA generates a polymorphism that 
has been shown to be a factor of prediction of 
the survival in patients with dilated 
cardiomyopathy [11]. 
 
The advance of medical science shows a 
participation of genetic background and its 
relations with the clinic evidence. The studies of 
polymorphisms demonstrate that could be 
considered as risks of factors for the 
development of cardiovascular pathologies, and 
would considered good tool with prognostic value 
in different entities [12]. Many of the studies were 
conducted in Caucasian European populations, 
however in Argentina there were few studies that 
showed the link between polymorphisms and 
clinical outcome. The Argentina populations 
consisting of European and native people. A 
study of Argentina community was necessary for 
observation of typical genetic variantions of this 
population. It also could offer potentially valuable 
screening tools for treating the hypertension and 
understandin of it´s pathogenesis. 
 
Based on the evidence, we proposed to       
know, whether polymorphisms are involved in   
the clinical symptomatology variety of the 
hypertensives. We analyzed the genetic 
frequencies the +138/ex1 I/D A polymorphism in 
the ET-1 gene and the T/C His323His 
polymorphism in the EDNRA gene associated to 
the values of biochemical variables in plasma in 
a cohort of patients defined as hypertensive. 
 
2. MATERIALS AND METHODS 
 
2.1 Subjects 
 
A total of 136 patients ranged from 30 to 70 
years of age, were not related to each other, 
regularly attended the Hypertension Service at 
the Internal Medicine Department of Córdoba 
Hospital considered hypertensive with similar 
disease-background, were recruited for a 
descriptive study. The hypertensive status was 
defined according to JNC VII [13]. A total of 59 
individuals were considered as healthy controls, 
as they had normal systolic and diastolic arterial 
pressure (<140 - 90 mm Hg) and had never been 
treated with anti-hypertensive medication. All 
individuals completed a questionnaire about their 
family history of cardiovascular diseases and 
were subjected to a physical examination. The 
patients were treated according to the Helsinki 
declaration and gave signed informed consent 
prior to admission. This study was approved     
by the institution’s Ethics Committee. Diabetic 
patients, pregnant women, patients with 
secondary hypertension, obese individuals, and 
individuals suffering from any episode acute at 
the time of the interview were excluded from the 
study. Once the patients were diagnosed, the 
blood samples were obtained, and the non-
invasive tests were conducted, the patients   
were medicated and assisted with standard 
treatments. 
 
A resting 12-lead electrocardiogram (ECG), a    
2-dimensional color Doppler transthoracic 
echocardiograph (EcoCG) and thoracic X-rays 
(Rx) were obtained for all subjects on the 
Cordoba Hospital. Independent observers scored 
the non-invasive test results.  
 
Patients diagnosed as hypertensive (HT) were 
classified as asymptomatic if, besides blood 
pressure values above 90 and 140 mmHg, they 
had normal a thoracic Rx, ECG, EcoCG, and 
clinical data. Patients were classified as 
symptomatic when the blood pressure values 
were above 90 and 140 mmHg and at least one 
of the other tests was abnormal.  
 
2.2 Sample Collection and DNA 
Extraction 
 
Blood samples were collected from each subject 
at the Central Hospital Laboratory. hepatic and 
renal function, plasma lipid levels, and metabolic 
profiles were measured using the Dimension 
Analyzer (Siemens, Germany). A 1-mL aliquot of 
blood was used for DNA isolation according to 
conventional methods [14]. Polymerase chain 
reaction and restriction fragment analysis (PCR-
RFLP) was used to identify single nucleotide 
polymorphisms (SNPs) according to reference 
[15,16]. 
 
2.3 Polymorphisms Analysis 
 
The polymorphisms were determined by PCR 
amplification of 100 ng DNA per patient. The 
amplification was performed in a Perkin Elmer 
Cetus Thermocycler (Waltham, MA, USA). All 
reactions were performed in duplicate, and 
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positive and negative controls were used for both 
the PCR amplifications and the restriction 
digestion enzyme assays [14]. The analysis of 
the ±138 EX1 I /D A polymorphism in the ET-1 
gene and C/T His323His polymorphism in the 
EDNRA gene were amplified by PCR with 
specific primers. The fragments were treated with 
the enzyme restriction for each polymorphisms 
[15,16]. Following digestion, the products were 
separated by electrophoresis on a 3% agarose 
gel or an 8% polyacrylamide gel and stained with 
ethidium bromide. When the results were 
ambiguous, the amplification products were 
sequenced to corroborate the specificity of the 
amplified fragment (ABI PRISM 310; Applied 
Biosystems,USA). 
 
2.4 Statistical Analysis 
 
Allelic and genotypic polymorphism frequencies 
were obtained from direct counts. The Hardy-
Weinberg equilibrium was calculated. The 
differences in the clinical and biochemical 
variables between the groups were calculated 
with either the Chi-squared test or the          
Irwin-Fisher test. A P-value below 0.05           
was considered statistically significant. The 
association between clinical variables and the 
polymorphic marker genotypes was analyzed 
with ANOVA and correlation analyses. The 
probability ratio and the confidence interval 
(95%) were calculated in order to express the 
degree of linkage between the polymorphisms 
and clinical parameters. Statistical calculations 
were conducted with Infostat vs2007e software 
and the power of the study by Minitab 17 test.  
 
3. RESULTS 
  
3.1 Population Characteristics 
 
Table 1 shows the demographic data and the 
main clinical characteristics of the patients 
included in the study. 
 
3.2 Genetic Polymorphism Analysis 
 
The genotypic frequencies of the +138/ex1 I/D A 
polymorphism in the ET-1 gene and the 
His323His polymorphism in the EDNRA gene 
were analyzed. Their distributions were 
compared to those in the healthy control group, 
which comprised normotensive individuals 
without cardiac clinical manifestations. The 
distribution followed Hardy-Weinberg equilibrium. 
No statistically significant differences in the 
genotype distributions for either polymorphism 
were detected between the healthy control      
and hypertensive populations (Table 2). The 
frequencies of the TT genotype for the type A 
receptor polymorphism were 12.5% and 14% in 
the patients and healthy controls, respectively. 
The I/I genotype frequencies for the ET-1 
polymorphism were 17% in the HT patients and 
29% in the healthy controls. These frequencies 
are similar to those reported by other groups 
[16,17]. Due to the small number of homozygotes 
for each polymorphism, and with the objective of 
achieving a more rigorous statistical analysis, the 
less-frequent homozygotes were combined with 
the heterozygotes for all subsequent analyses.  
 
The distribution of genotypic frequencies for the 
C/T His323His EDNRA polymorphism analyzed 
by Pearson’s Chi-squared test differed between 
the female and male populations, because       
the CC genotype was less frequent in males    
(16 (30%) vs 34 (43.8%) P=0.02). No statistically 
significant association was found between men 
carried the polymorphisms and the degree of 
cardiovascular disease. 
 
The mean values and standard deviations of the 
biochemical parameters in the plasma from 
asymptomatic and symptomatic patients were 
assessed with the non-parametric Kruskal-Wallis 
test and were arranged according to genotype 
(Table 3). The mean values in the asymptomatic 
patients with the D/I + I/I genotype were as 
follows: 23±6.5 mU/mL GPT, 3.86±1.02 mg/dL 
UA, 180 mg/dL cholesterol, and 97.24 mg/dL 
LDL, which corresponded to normal values. 
Therefore, the D/I + I/I genotype in asymptomatic 
HT patients is associated with normal values of 
the aforementioned biochemical parameters.      
A similar profile was observed in asymptomatic 
HT patients with the CC genotype,               
which positively interacted with lower plasma 
values of AP (198±55 mU/mL) and cholesterol 
(172.3±43.05 mg/dL). 
 
Finally, it was determined whether the allele 
frequencies (C or T) of the His323His 
polymorphism in the EDNRA gene correlated   
with the degree of heart disease. For both 
genders, the T allele was statistically less               
frequent amongst asymptomatic HT patients                  
(16 individuals, 26%) compared to the 59 
patients in second and third degree symptomatic. 
The latter group represented 40% of the sample 
size with the T allele. The presence of the T 
allele positively correlated (r = 0.54) with the 
degree of cardiovascular compromise (P= .002) 
and the interval value [-1, +1]. The frequency of 
T allele carriers among the symptomatic    
patients with less cardiovascular compromise 
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(asymptomatic and first-degree symptomatic) 
was similar to that observed in the healthy 
control group. 
 
Table 1. Demographic data and clinical 
characteristics of patients 
 
N 136 
Age (years) 56±14 
Gender  
Female 81 (59.7%) 
Male 55 (40.3%) 
GPT † 28.3±14 
AP † 217.9±23.1 
TG † 161±83 
Cholesterol † 214±57 
HDL-chol † 49±12 
LDL † 124±36 
Uric Acid † 4.49±1.35 
Rx  
 No alterations 30 (22%) 
 First-degree cardiomegaly   42 (31%) 
 Second-degree 
cardiomegaly  
57 (42%) 
 Third- and fourth-degree 
cardiomegaly  
7 (5%) 
ECG  
 no alterations 32 (23.5%) 
 CRBBB + LAHB + LVHB  47 (34.4%) 
 + ischemia 56 (41.0%) 
 + AF or complete auricular 
block  
1 (0.7%) 
EcoCG  
 No alterations  81 (59.8%) 
 EF 50% + chamber dilation  28 (20.5%) 
 EF below 40% 9 (6.6%) 
 EF below 30% + chamber 
dilation 
18 (13.1%) 
The numbers represent the numbers of individuals; 
percentages are in parentheses. † are expressed as 
the mean ± the standard deviation. Normal Values: 
GPT (glutamic/pyruvate transaminase), 41 mUI/ml; AP 
(alkaline phosphatase) < 270 UI/L; TG (triglycerides), 
< 150 mg/dl; Cholesterol, < 200 mg/dl; HDL-chol (high 
density lipoprotein-cholesterol), > 40 mg/dl; LDL (low-
density lipoprotein) <100mg/dl and UA (uric acid), < 6 
mg/dL.; CRBBB, complete right bundle branch block; 
LAHB, left auricular hemiblock; LVHB, left ventricular 
hemiblock; AF, auricular fibrillation; EF, ejection 
fraction 
 
3.3 Power of the Study 
 
On power calculations of the study was 
estimated to be 0.823 (82.3%) for 136 
hypertensions patients using +138/ex1 I/D A 
polymorphism for ET-1 gene as an example, with 
the probability of type 1 error being 0.05. 
4. DISCUSSION 
 
Our first observation in this study was the rare 
occurrence of the CC genotype of the EDNRA 
gene in male subjects (P=.02). Furthermore, the 
CC genotype is associated with normal plasma 
AP activity and cholesterol levels in carriers who 
are clinically characterized at recruitment without 
injury in organ target. Although the sample is 
small and with the risk to committing type 1 
errors. We can speculate that patients carrying 
the CC genotype would have a better prognosis 
for symptoms development because plasma 
cholesterol level is a risk factor of cardiovascular 
diseases. Additionally, it was shown that, for both 
genders, the T allele of the same polymorphism 
positively correlated with more severe damage    
(r = 0.54, P= .002). 
 
The C/T His323His polymorphism, has been 
linked to decreased survival in subjects with 
dilated cardiomyopathy. Carriers of the T      
allele have worse cumulative survival, compared 
to non-carriers [11]. Colombo et al. [17] reported 
that this polymorphism was linked to a 
significantly higher risk of cardiac failure. 
Furthermore, the His323His polymorphism is a 
prognostic predictor irrespective of age, clinical 
class according to the New York Heart 
Association, the left ventricular fraction, and the 
end-diastolic diameter [17].  Recently, Calabró et 
al. [16] described an association between the TT 
genotype, pulmonary resistance, and decreased 
cardiac index via cardiac catheterism in patients 
with pulmonary arterial hypertension. The 
mechanisms that would explain the potential 
effects of the TT genotype remain unknown 
because the substitution of thymidine (T) for 
cytosine (C) does not alter the amino acid 
sequence of the receptor. How a synonymous 
codon could have such a profound effect on the 
phenotype has yet to be understood. A possible 
explanation could be that this polymorphism 
affects gene expression or post-translational 
modifications. Another potential explanation 
could be that the His323His variant causes a 
binding disequilibrium with another functional 
variant [11]. Despite this, Holzhauser L et al. [12] 
encourages the study of the polymorphisms of 
endothelin receptors. Because of it might lead to 
altered endothelin signaling and influence the 
response to endothelin receptor antagonist 
therapy in pulmonary arterial hypertension in light 
of pharmacogenetics. 
 
HT pathogenesis is characterized by significant 
vascular resistance due to the biochemical and 
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cellular modifications that lead to a dysfunctional 
endothelium, vasoconstriction, arterial wall 
thickening, and thrombosis. ET-1 plays an 
important vasoconstrictive role, and its plasma 
levels are elevated in several diseases [18-20]. 
Popowski et al. [9] found that homozygote I/I 
carriers expressed significantly higher levels of 
ET-1 (3.9-fold higher than the D/D variant). ET-1 
increases the sympathetic activity induced by 
stress and arterial vasoconstriction. ET-1   
activity damages the endothelium-dependent 
vasodilating function in hypertensive patients [2]. 
Therefore, functional ET-1 gene variants     
would contribute to the development of arterial   
pressure alterations [4]. Our study shows that 
hypertensive subjects who carry the A insertion, 
either as heterozygotes (I/D) or homozygotes 
(I/I), have normal plasma GPT, UA, cholesterol, 
and LDL levels. This suggests that a better 
metabolic predisposition compensates for HT. 
However, it has not been possible to establish a 
correlation between the degree of cardiovascular 
disease and I/I genotype carrier status for        
the +138/ex1 I/D polymorphism. This is likely 
because several factors must act together in 
order to display a phenotype. 
 
Table 2. Genotype distributions of the +138/ex1 ins/del A polymorphism in the ET-1 gene and 
the C/T His323His polymorphism in the EDNRA gene in the patients and controls 
 
Genetic polymorphism  Healthy controls Hypertensive patients P-value 
+138/ex1 I/D A, ET-1 gene  n (%) n (%) 
D/D 10 (17) 25 (18.3)  
D/I 32 (54) 88 (65)  
I/I 17 (29) 23 (17) P = .184 
C/T His323His, EDNRA gene    
CC 21 (36) 45 (33.3)  
CT 30 (50) 74 (54.3)  
TT 8 (14) 17 (12.5) P = .180 
The numbers represent the numbers of individuals; percentages are in parentheses. Significance level, p < 0.05. 
D, deletion of 3 adenines (A); I, insertion of 4 A; C, cytosine; T, thymidine 
 
Table 3. Polymorphism analysis for endothelin-1 and its type a receptor and symptomatic/ 
asymptomatic conditions 
 
Polymorphism genotypes  Asymptomatic Symptomatic P-value 
Mean (SD) Mean (SD) 
+138/ex1 I/D A, ET-1 gene  
 GPT (mU/mL) 
D/D 37.00 (12.91) 31.03 (17.83) .041 
D/I + I/I 23.00 (6.54)* 31.85 (34.63)  
 UA (mg/dL) 
D/D  5.29 (1.72) 5.60 (1.59) .001 
D/I + I/I  3.86 (1.02)* 5.54 (1.61)  
 Cholesterol (mg/dL) 
D/D  206.0 (50.63) 224.18 (59.96)  
D/I + I/I  180.0 (52.07)* 223.27 (54.57) .032 
 LDL (mg/dL) 
D/D  130.29 (37.65) 124.64 (31.21) .013 
D/I + I/I  97.24 (30.06)* 127.64 (33.67)  
C/T His323His, EDNRA gene AP (mU/L) 
CC 198.50 (55.43)* 264.51 (88.26) .032 
CT + TT 210.57 (56.82) 254.51 (67.00)  
 Cholesterol (mg/dL) 
CC 172.30 (43.05)* 241.02 (64.84) .003 
CT + TT 198.50 (56.45) 205.28 (40.16)  
Asymptomatic, patients with normal Rx, ECG, and EcoCG records; Symptomatic, patients with altered Rx, ECG, 
and EcoCG records; D, deletion of 3 adenines (A); I, insertion of 4 A; C, cytosine; T, thymidine. GPT, 
glutamic/pyruvate transaminase; UA, uric acid; LDL, low-density lipoprotein; AP, alkaline phosphatase.  
* indicates the genotype with a significant difference. The numbers represent the mean values, standard 
deviations are in parentheses 
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Studies that have linked SNPs to functional 
pathological effects have not been repeated by 
other research groups. Similarly, the majority of 
studies that link polymorphisms to phenotypes 
and/or diseases are either cross-sectional 
studies or are limited by low patient availability. 
The latter is true for the current study, which 
makes such studies prone to possible sample 
selection bias. Validation of genotype-phenotype 
association studies requires replication of        
the results from a set of independent data and in 
a larger sample. Because, the low number of 
cases may causes a type 1 statistical error.         
It is necessary to be cautious before drawing 
conclusions. Even if the observations are 
statistically significant, we cannot prove that     
the polymorphisms in the ET-1 and type A 
receptor genes play direct roles in hypertensive 
symptomatology. For this purpose, the patient 
genotypes must be determined early and a 
follow-up study conducted to prove that the 
genotype plays a role in symptom expression 
and development [3,4,11,17]. Probably in this 
study the pathogenesis of HT is incompletely 
characterized, but it is likely to be multifactorial, 
involving the interaction between the genetic 
milieu and the environment of the individual.  
 
5. CONCLUSION 
 
It was observed that genotype distributions for 
both studied polymorphisms were the same for 
healthy control and hypertensive populations. 
Besides, the CC genotype from EDNRA 
polymorphism was less frequent in males. In 
asymptomatic HT patients, the CC genotype was 
associated with normal plasma values of          
AP and cholesterol. Asymptomatic hypertensives 
patients with the D/I + I/I genotype from 
polymorphism from ET-1 gene, had normal 
values of GPT activity and plasmatic 
concentrations of  UA, cholesterol and LDL 
Although our results do not explain how the 
polymorphisms could directly affect cardio-
vascular disease pathogenesis and complica-
tions, it does not mean that a certain genetic 
background could play a role in exacerbating HT 
symptomatology in patients. We propose that, to 
follow the study to increase the sample size and 
the inclusion of a group of patients absence of 
HT, but with similar conditions at the image 
studies examinations as disease control group. 
The challenge now is to determine how genetic 
variation influences the response to these 
stressors. 
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